Specific treatment of patients with diabetic nephropathy can be divided into 4 major arenas: cardiovascular risk reduction, glycemic control, blood pressure control, and inhibition of the renin‐angiotensin system (RAS).1 Our previous studies have demonstrated that FGF1 administration protected against renal injury by reducing inflammation.13 Based on previous study, our current study had further confirmed that FGF1 administration ameliorated diabetes‐induced glomerular damage and interstitial fibrosis. The gene discussed is FGF1; the disease is diabetes mellitus.